Stocks · News reference

Curis Strengthens Oncology Pipeline Outlook With Strong TakeAim Lymphoma Response Rates

Jul 22, 2026, 5:04 PMVandana Singh

Curis shares positive updated clinical data for emavusertib and increases its year-end guidance for the TakeAim CLL study.

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaAug 18, 2026, 9:06 PMBenzinga Insights
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers Tenon Medical (NASDAQ:TNON) shares moved upwards by 70.3% to $9.28 during Tuesday's after-market session. The market value of their outstanding shares is at $3.2 million. The company's, Q2 earnings came
Read original at benzinga
AHG APUS CRIS HCWB IMCC
BenzingaAug 17, 2026, 10:14 AMBenzinga Newsdesk
HC Wainwright & Co. Reiterates Buy on Curis, Maintains $43 Price Target
HC Wainwright & Co. analyst Sara Nik reiterates Curis (NASDAQ:CRIS) with a Buy and maintains $43 price target.
Read original at benzinga
CRIS
BenzingaAug 11, 2026, 5:06 PMBenzinga Insights
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Neuronetics (NASDAQ:STIM) shares moved upwards by 34.1% to $2.91 during Tuesday's regular session. The market value of their outstanding shares is at $151.0 million. As per the press release, Q2 earnings
Read original at benzinga
ACB AIXC ALMR CRIS GRI
BenzingaJul 30, 2026, 12:11 PMBenzinga Newsdesk
Curis Announces First Five Patients Dosed In TakeAim CLL Study Of Emavusertib With Zanubrutinib; Reaffirms Initial Data In 5-10 Patients In December 2026
Read original at benzinga
CRIS